Review of Clinical Trials in Head Injury Yields Important Recommendations, as Reported in Journal of Neurotrauma

6/3/2002 5:16:00 PM
LARCHMONT, N.Y., Jun 3, 2002 (BUSINESS WIRE) -- Recognizing the importance of traumatic brain injury (TBI), and the failure of several recent clinical trials to demonstrate successful outcomes following treatment for head injury, the National Institute of Neurological Disorders and Stroke (NINDS) sponsored a workshop aimed at reviewing past trials and issuing a series of recommendations to guide future clinical studies in TBI. "Clinical Trials in Head Injury," a paper summarizing the key findings of the workshop and the recommendations of the Clinical Trials in Head Injury Study Group, appears in the May 2002 issue (Volume 19, Number 5) of the Journal of Neurotrauma. This paper will serve as a roadmap for future studies of TBI. The Journal of Neurotrauma is a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). This paper will be available free online at www.liebertpub.com/NEU

CBS MARKETWATCH TOP NEWS
El Paso calls plunge 'unwarranted' after suicide news
Tech descent mauls U.S. stocks
Tyco CEO Kozlowski resigns amid tax-probe report
Nasdaq erasing botched Knight trades




Sign up for FREE e-newsletters






Get the latest news updated 500 times a day by our 70+ reporters.



Primary authors and study group organizers Raj K. Narayan, M.D., Department of Neurosurgery, Temple University Hospital, Philadelphia, PA, and Mary Ellen Michel, Ph.D., Program Director, Traumatic Brain Injury, NINDS, Bethesda, MD, highlight the global public health problem posed by TBI, with approximately 500,000 new cases each year in the United States alone. Of the 10%, or 50,000 patients who suffer severe TBI, about one third will die of their injuries. Among the survivors of TBI, many will have significant long-term disability.

Among the key recommendations of the Study Group was for researchers to obtain a better understanding of the pathophysiology of TBI through further research, and to obtain adequate preclinical data by studying severe TBI, and testing novel therapeutic interventions in animal models of head injury before initiating clinical trials. To minimize the possibility of failure in future clinical trails, the Study Group recommended targeting treatment to the subpopulation of patients who are most likely to benefit from treatment, determining that the drugs used can reach the brain, standardizing patient management within and across trauma centers, and selecting the most sensitive indicators of outcome in the evaluation of patients.

The Journal of Neurotrauma is an authoritative peer-reviewed journal published monthly in print and online that focuses on the latest advances in the clinical and laboratory investigation of traumatic brain and spinal cord injury. Emphasis is on the basic pathobiology of injury to the nervous system, and the papers and reviews evaluate preclinical and clinical trails targeted at improving the early management and long-term care and recovery of patients with traumatic brain injury. The Journal of Neurotrauma is the official journal of the National Neurotrauma Society and the International Neurotrauma Society. A complete table of contents and a free sample issue may be viewed online at www.liebertpub.com/NEU.
Mary Ann Liebert, Inc., is a privately, held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research. Its biotechnology trade magazine, Genetic Engineering News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsletters is available at www.liebertpub.com.
CONTACT: Mary Ann Liebert, Inc. Vicki Cohn, 914/834-3100, ext.617 vcohn@liebertpub.comURL: http://www.businesswire.comToday's News On The Net - Business Wire's full file on the Internetwith Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.